We are live on ! Find out more
HUMA icon

Humacyte

70 hedge funds and large institutions have $74M invested in Humacyte in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 11

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

33% more call options, than puts

Call options by funds: $1.24M | Put options by funds: $932K

15% more funds holding

Funds holding: 6170 (+9)

7% more capital invested

Capital invested by funds: $69M → $74M (+$4.98M)

0.94% more ownership

Funds ownership: 9.25%10.18% (+0.94%)

Holders
70
Holders Change
+9
Holders Change %
+14.75%
% of All Funds
1.1%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
25
Increased
23
Reduced
11
Closed
15
Calls
$1.24M
Puts
$932K
Net Calls
+$308K
Net Calls Change
-$1.41M
Name Holding Trade Value Shares
Change
Change in
Stake
MS
76
Maven Securities
Jersey
-$1.45M -200,000 Closed
LP
77
LMR Partners
United Kingdom
-$268K -36,960 Closed
Two Sigma Investments
78
Two Sigma Investments
New York
-$225K -31,061 Closed
VF
79
Virtu Financial
New York
-$144K -19,851 Closed
Zurich Cantonal Bank
80
Zurich Cantonal Bank
Switzerland
-$96K -13,230 Closed
VFIC
81
Valley Forge Investment Consultants
Pennsylvania
-$80K -11,000 Closed
Belvedere Trading
82
Belvedere Trading
Illinois
-$52K -10,035 Closed
EVM
83
Eaton Vance Management
Massachusetts
-$7K -1,000 Closed
PNC Financial Services Group
84
PNC Financial Services Group
Pennsylvania
-$7K -1,000 Closed
LC
85
Lindbrook Capital
California
-$1K -200 Closed

HUMA Hedge Fund Activity: Q1 2022 in Review

70 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q1 2022, worth a combined $74M — up 7.2% from $69M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new HUMA positions and 15 closed out — a net gain of 10 holders — while 23 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $7.3M. The largest seller was UBS O'Connor, exiting entirely with an estimated $6.53M sold.

  • 70 institutional investors held Humacyte (HUMA) as of Q1 2022, up from 61 in Q4 2021.
  • Funds reported $74M of Humacyte stock for Q1 2022, up 7.2% quarter-over-quarter.
  • 25 funds opened new Humacyte positions in Q1 2022 and 15 closed out, a net change of +10 holders.
  • The largest Humacyte buyer in Q1 2022 was Vanguard Group, an estimated $7.3M added.
  • The largest Humacyte seller in Q1 2022 was UBS O'Connor, an estimated $6.53M sold.

Based on aggregated 13F filings for Q1 2022.